Biocytogen-B Shares Surge Over 7% Intraday on Strong Full-Year Profit Guidance and Key Collaboration Milestone

Stock News03-16

Biocytogen-B (02315) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.9%, trading at HK$57.45, with a turnover of HK$33.73 million. The company previously released its 2025 performance forecast, showing preliminary accounting data indicating revenue of approximately RMB 1.379 billion and net profit attributable to shareholders of RMB 173 million, representing year-on-year increases of 40.63% and 416.37%, respectively. Additionally, the company's licensed B7H3/PTK7 ADC candidate drug IDE034 to IDEAYA has completed enrollment of the first patient in its Phase 1 clinical trial. IDEAYA will pay Biocytogen a milestone payment of $5 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165728195?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 15:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165728195","market":"fut","top_or_hot":-1,"title":"Biocytogen-B Shares Surge Over 7% Intraday on Strong Full-Year Profit Guidance and Key Collaboration Milestone","media":"Stock News","content":"<p>Biocytogen-B (02315) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.9%, trading at HK$57.45, with a turnover of HK$33.73 million. The company previously released its 2025 performance forecast, showing preliminary accounting data indicating revenue of approximately RMB 1.379 billion and net profit attributable to shareholders of RMB 173 million, representing year-on-year increases of 40.63% and 416.37%, respectively. Additionally, the company's licensed B7H3/PTK7 ADC candidate drug IDE034 to IDEAYA has completed enrollment of the first patient in its Phase 1 clinical trial. IDEAYA will pay Biocytogen a milestone payment of $5 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen-B Shares Surge Over 7% Intraday on Strong Full-Year Profit Guidance and Key Collaboration Milestone</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen-B Shares Surge Over 7% Intraday on Strong Full-Year Profit Guidance and Key Collaboration Milestone\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-16 15:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen-B (02315) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.9%, trading at HK$57.45, with a turnover of HK$33.73 million. The company previously released its 2025 performance forecast, showing preliminary accounting data indicating revenue of approximately RMB 1.379 billion and net profit attributable to shareholders of RMB 173 million, representing year-on-year increases of 40.63% and 416.37%, respectively. Additionally, the company's licensed B7H3/PTK7 ADC candidate drug IDE034 to IDEAYA has completed enrollment of the first patient in its Phase 1 clinical trial. IDEAYA will pay Biocytogen a milestone payment of $5 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1165728195","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165728195","pubTimestamp":1773647438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Biocytogen-B (02315) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.9%, trading at HK$57.45, with a turnover of HK$33.73 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","02315":"百奥赛图-B","VXUS":"国际股票ETF-Vanguard"},"translate_title":"由于强劲的全年利润指引和关键合作里程碑，百奥赛图-B股价盘中飙升超过7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1,"VXUS":1},"content_text":"Biocytogen-B (02315) saw its shares rise more than 7% during the trading session. At the time of writing, the stock was up 5.9%, trading at HK$57.45, with a turnover of HK$33.73 million. The company previously released its 2025 performance forecast, showing preliminary accounting data indicating revenue of approximately RMB 1.379 billion and net profit attributable to shareholders of RMB 173 million, representing year-on-year increases of 40.63% and 416.37%, respectively. Additionally, the company's licensed B7H3/PTK7 ADC candidate drug IDE034 to IDEAYA has completed enrollment of the first patient in its Phase 1 clinical trial. IDEAYA will pay Biocytogen a milestone payment of $5 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165728195","isCrawlerRequest":true}